Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence

JW Eikelboom, E Lonn, J Genest, G Hankey, S Yusuf

    Research output: Contribution to journalReview article

    Abstract

    Purpose: To review epidemiologic studies on the association between homocyst(e)ine level and risk for cardiovascular disease and the potential benefits of homocysteine-decreasing therapies.

    Data Sources: Computerized and manual searches of the literature on total homocysteine levels and cardiovascular disease.

    Study Selection: Prospective studies and major retrospective epidemiologic studies evaluating the association between homocyst(e)ine levels and cardiovascular disease and the association between blood levels or dietary intake of folate, vitamin B-6, and vitamin B-12 and cardiovascular disease.

    Data Extraction: Relevant data on patient population, plasma homocyst(e)ine levels, duration of follow-up, and main results were extracted from studies that met the inclusion criteria.

    Data Synthesis: The designs and results of studies included in this review are summarized. A formal metaanalysis was not performed because the studies were heterogeneous in method and design.

    Conclusions: Results of epidemiologic studies suggest that moderately elevated plasma or serum homocyst(e)ine levels are prevalent in the general population and are associated with an increased risk for cardiovascular disease, independent of classic cardiovascular risk factors. Simple, inexpensive, nontoxic therapy with folic acid, vitamin B-6, and vitamin B-12 reduces plasma homocyst(e)ine levels. Although the association between homocyst(e)ine levels and cardiovascular disease is generally strong and biologically plausible, the data from the prospective studies are less consistent. In addition, epidemiologic observations of an association between hyperhomocyst(e)inemia and cardiovascular risk do not prove the existence of a causal relation. Therefore, the effectiveness of folate, vitamin B-6, and vitamin B-12 in reducing cardiovascular morbidity and mortality requires rigorous testing in randomized clinical trials. Several such trials are under way; their results may greatly affect cardiovascular morbidity and mortality, given the simplicity and low cost of vitamin therapy.

    Original languageEnglish
    Pages (from-to)363-375
    Number of pages13
    JournalAnnals of Internal Medicine
    Volume131
    Issue number5
    DOIs
    Publication statusPublished - 7 Sep 1999

    Cite this